The development of a fully effective vaccine against disease caused by all group B meningococcal (MenB) strains remains the critical goal for prevention of meningococcal meningitis and septicaemia. The recent announcement of one potential multicomponent vaccine is encouraging, but there is likely to be a continuing need for a vaccine effective against all strains.
Vaccines work by using a harmless fragment of an infectious agent to “trick” the immune system to produce protective antibodies as it would during an actual infection, so protecting against further infection. To develop such vaccines requires the identification of the few individual bacterial components (antigens), from many hundreds, which have the ability to produce effective immunity. Previous research has demonstrated that most people develop immunity to meningococcal infection when they carry meningococcal bacteria in the back of their throat.
During previous work supported by us (formally Meningitis UK), Professor Heckels identified seven such antigens and began the task of producing them in pure form for vaccine studies. One antigen was purified, incorporated into a vaccine formulation and used for immunisation. The preliminary results were promising and further funding was secured to continue the research.
This project aimed to evaluate the ability of the remaining individual antigens to induce protective immunity against a wide range of meningococcal strains, to select the most promising ones and combine them in a multicomponent formulation. This vaccine can then be tested for its ability to induce protective immunity against a wide range of group B, and other, meningococcal strains.
The project is now completed and has achieved some very promising results. Of the seven original meningococcal proteins, three have been identified which can be easily purified and induce the production of antibodies that could protect against a wide range of meningococcal strains. These antigens are therefore strong candidates, either singly or combined, for inclusion in a vaccine designed to protect against the diverse range of Men B strains occurring in the community. Two other proteins also have the potential for use in a multicomponent vaccine.
The researchers would like to continue this work and produce a multicomponent vaccine for pre-clinical trials.
The difference it will make
This project has discovered different meningococcal proteins that could be used to produce a more effective vaccine to protect against not only MenB disease, but also other meningococcal strains.
Sharing these results
The results of the studies with antigen F have been published in the journal Vaccine
Another paper has been submitted for publication and three further manuscripts are planned.
Help support this research
This research is only made possible by the generous support of people like YOU. Help us continue by donating
or raising funds for our work. On behalf of everyone who will benefit, now and in the future.
Professor John Heckels
University of Southampton
If you would like more information about this project, or our research in general, please contact us on email@example.com